Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Free Report) CFO Michael Celano purchased 18,460 shares of Larimar Therapeutics stock in a transaction that occurred on Wednesday, November 11th. The shares were bought at an average cost of $2.71 per share, with a total value of $50,026.60. Following the completion of the transaction, the chief financial officer directly owned 234,245 shares of the company’s stock, valued at approximately $634,803.95. The trade was a 8.55% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Larimar Therapeutics Price Performance
LRMR stock traded up $0.32 during mid-day trading on Friday, reaching $3.02. The company had a trading volume of 2,531,459 shares, compared to its average volume of 1,257,255. The stock has a 50 day simple moving average of $2.93 and a two-hundred day simple moving average of $3.76. The company has a market capitalization of $313.72 million, a price-to-earnings ratio of -1.55 and a beta of 0.73. Larimar Therapeutics, Inc. has a 52 week low of $1.91 and a 52 week high of $6.42.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in LRMR. Blue Owl Capital Holdings LP raised its stake in Larimar Therapeutics by 0.3% in the 3rd quarter. Blue Owl Capital Holdings LP now owns 9,923,904 shares of the company’s stock valued at $31,707,000 after acquiring an additional 32,147 shares during the period. BlackRock Inc. bought a new position in Larimar Therapeutics during the second quarter worth $17,318,000. Marshall Wace LLP boosted its position in Larimar Therapeutics by 9.1% during the third quarter. Marshall Wace LLP now owns 2,195,954 shares of the company’s stock worth $7,005,000 after purchasing an additional 183,496 shares during the period. AIGH Capital Management LLC bought a new position in Larimar Therapeutics during the third quarter worth $5,911,000. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Larimar Therapeutics by 143.8% in the first quarter. Dimensional Fund Advisors LP now owns 798,462 shares of the company’s stock valued at $3,592,000 after purchasing an additional 470,968 shares during the last quarter. 91.92% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several equities research analysts have recently commented on the company. Wedbush reissued an “outperform” rating on shares of Larimar Therapeutics in a report on Tuesday, November 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Larimar Therapeutics in a report on Thursday, October 15th. Wall Street Zen lowered shares of Larimar Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday. Finally, Leerink Partners initiated coverage on shares of Larimar Therapeutics in a research report on Monday, September 14th. They set an “outperform” rating and a $13.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $10.33.
Get Our Latest Research Report on LRMR
Top Larimar Therapeutics Stories
Here are a few of the latest stories about LRMR:
- Positive Sentiment: CEO Carole Ben-Maimon, CFO Michael Celano, COO John B. Jr. Harlow, insider Gopi Shankar, and directors Frank Thomas and Joseph Truitt together purchased 52,810 shares for roughly $195,000. Director Thomas Hamilton separately bought 70,000 shares for $186,900. Insider purchase report Hamilton SEC filing
- Neutral Sentiment: The supplied coverage also notes H.C. Wainwright maintained a Buy rating; no rating change or fresh price-moving catalyst was reported. Analyst rating report
About Larimar Therapeutics
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases. Its lead drug candidate is nomlabofusp, formerly known as CTI-1601, an engineered fusion protein designed to deliver frataxin to mitochondria. Nomlabofusp is being developed to treat Friedreich’s ataxia, a rare, inherited neurodegenerative disorder associated with insufficient frataxin. Larimar’s approach uses a cell-penetrating peptide to transport frataxin into cells and mitochondria, with the goal of addressing an underlying cause of the disease rather than only treating its symptoms.
Featured Stories
- Five stocks we like better than Larimar Therapeutics
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
